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Serum amyloid A primes microglia for
ATP-dependent interleukin-1β release
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Abstract
Background: Acute-phase response is a systemic reaction to environmental/inflammatory insults and involves
production of acute-phase proteins, including serum amyloid A (SAA). Interleukin-1β (IL-1β), a master regulator of
neuroinflammation produced by activated inflammatory cells of the myeloid lineage, in particular microglia, plays a key
role in the pathogenesis of acute and chronic diseases of the peripheral nervous system and CNS. IL-1β release is
promoted by ATP acting at the purinergic P2X7 receptor (P2X7R) in cells primed with toll-like receptor (TLR) ligands.
Methods: Purified (> 99%) microglia cultured from neonatal rat cortex and cerebellum were first primed with the
putative TLR4/TLR2 agonist SAA (recombinant human Apo-SAA) or the established TLR4 agonist lipopolysaccharide
(LPS) followed by addition of ATP. Expression of genes for the NLRP3 inflammasome, IL-1β, tumor necrosis factor-α
(TNF-α), and SAA1 was measured by quantitative real-time polymerase chain reaction (q-PCR). Intracellular and
extracellular amounts of IL-1β were determined by ELISA.
Results: Apo-SAA stimulated, in a time-dependent manner, the expression of NLRP3, IL-1β, and TNF-α in cortical
microglia, and produced a concentration-dependent increase in the intracellular content of IL-1β in these cells. A 2-h
‘priming’ of the microglia with Apo-SAA followed by addition of ATP for 1 h, resulting in a robust release of IL-1β into
the culture medium, with a concomitant reduction in its intracellular content. The selective P2X7R antagonist A740003
blocked ATP-dependent release of IL-1β. Microglia prepared from rat cerebellum displayed similar behaviors. As with
LPS, Apo-SAA upregulated SAA1 and TLR2 mRNA, and downregulated that of TLR4. LPS was less efficacious than Apo-
SAA, perhaps reflecting an action of the latter at TLR4 and TLR2. The TLR4 antagonist CLI-095 fully blocked the action
of LPS, but only partially that of Apo-SAA. Although the TLR2 antagonist CU-CPT22 was inactive against Apo-SAA, it
also failed to block the TLR2 agonist Pam3CSK4.
Conclusions: Microglia are central to the inflammatory process and a major source of IL-1β when activated. P2X7R-
triggered IL-1β maturation and export is thus likely to represent an important contributor to this cytokine pool. Given
that SAA is detected in Alzheimer disease and multiple sclerosis brain, together with IL-1β-immunopositive microglia,
these findings propose a link between P2X7R, SAA, and IL-1β in CNS pathophysiology.
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Background
Inflammatory conditions are marked by the production
of mediators such as cytokines, chemokines, reactive
oxygen species, and acute phase proteins that are key el-
ements of the accompanying physiological and metabolic
changes. C-reactive protein, complement proteins, and
serum amyloid A protein (SAA) are some of the
principal acute phase proteins, mainly generated in the
liver and released into the systemic circulation in re-
sponse to inflammation [1, 2]. SAA is the generic name
of a family of proteins that share high levels of sequence
homology but are encoded by different genes [3].
Humans possess four SAA genes (SAA1, SAA2, SAA3,
and SAA4) mapped in a 150-kb region of chromosome
11p15.115. Mice also have four SAA genes whose pro-
tein products are highly homologous to their human
counterparts [3]. Inducible expression is characteristic of
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all acute-phase SAAs including SAA1 and SAA2.
Extra-hepatic expression of SAA has been reported as
well [4].
Central nervous system (CNS) disorders are charac-
terized by central activation of innate immunity and
activation of a potent peripheral acute phase response
that influences central inflammation and contributes
to poor outcome [5]. Syrian hamsters injected system-
ically with lipopolysaccharide (LPS) had elevated
levels of mRNA for Apo-SAA in all tissues examined,
including brain [6]. While not detectable in normal
brain, SAA protein has been found in Alzheimer dis-
ease (AD) brain, along with SAA gene expression in
multiple sclerosis (MS) brain tissue [7]. Elevated SAA
concentration was described in cerebrospinal fluid of
AD subjects [8], as well as SAA immunoreactivity
that co-localized with amyloid β-peptide deposits in
AD brain [9]. Induction of a systemic acute phase re-
sponse in SAA transgenic mice enhanced amyloid
β-peptide deposition [10]. Further, Chung et al. [11]
reported a much stronger immunostaining of SAA in
brain of patients with neurologically confirmed AD
and MS in comparison to unaffected regions and
non-AD/MS brain. Barbierato et al. [12] recently
demonstrated that cortical glia responds to
pro-inflammatory agents (LPS, tumor necrosis factor
alpha (TNF-α), Apo-SAA) by upregulating their ex-
pression of Saa1.
Interleukin-1β (IL-1β), a master regulator of neuroin-
flammation [13] mainly produced by activated inflam-
matory cells of the myeloid lineage [14], contributes
importantly to cellular activation and cytokine produc-
tion. IL-1β plays a key role in the pathogenesis of acute
and chronic diseases of both the peripheral nervous sys-
tem and CNS [15–17]. LPS, a potent stimulus for IL-1β
synthesis by microglia is rather inefficient, given that
most of the secreted cytokine remains in the immature
(inactive) pro-form [18]. One of the molecules mainly
involved in IL-1β maturation is the purinoceptor
P2X7 (P2X7R), an ATP-gated ion channel that chiefly
acts through the recruitment of the NLRP3
inflammasome-caspase-1 complex [14, 19]. This acti-
vation process involves first recognition by toll-like
receptors (TLRs, a sub-family of pattern recognition
receptors) of exogenous (e.g., bacterial- and
virus-derived pathogens) or endogenous (e.g., compo-
nents of cell damage) stimuli to induce transcription
and translation of IL-1β (‘priming’). This is followed
by a secondary signal such as ATP to trigger forma-
tion of the inflammasome complex that leads to
caspase 1 activation and cleavage/release of IL-1β
[20–22]. P2X7R-triggered IL-1β maturation and ex-
port may thus represent a major contributor to this
cytokine pool [20, 23].
SAA appears to be an endogenous ligand for both
TLR4 [24–27] and TLR2 [28–31], despite having little
structural resemblance to the bacteria-derived ligands of
either receptor. Although SAA can upregulate the
NLRP3 inflammasome in peripheral immune cells [25]
and provoke mediator production in a variety of
non-neural cells, nothing is known about its ability to
stimulate IL-1β release from CNS glia in the presence of
ATP, a multi-target danger signal in the brain [32] in a
P2X7R-dependent manner. This is especially important,
given the growing body of data indicating that genetic or
pharmacological manipulation of P2X7Rs alters respon-
siveness in animal models of CNS neurological disorders
[33]. Recent studies suggest also that P2X7Rs regulate
the pathophysiology of psychiatric disorders, including
mood disorders [33]. The present study was undertaken
to examine the ability of ATP to promote the intracellu-
lar production, and release, of IL-1β from cortical micro-
glia stimulated with Apo-SAA, and the involvement of
P2X7R, TLR4, and TLR2.
Methods
Tissue culture media, antibiotics, fetal calf serum
(FCS), and NP40 cell lysis buffer (10×) were
purchased from Life Technologies (San Giuliano
Milanese, Italy); lipopolysaccaride (LPS) (Ultra-Pure
LPS-EB from E. coli 0111:B4 strain; only activates
TLR4), Pam3CSK4, and ethyl-(6R)-6-(N-(2-chloro-4--
fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
(CLI-095 or TAK 242) were from InvivoGen
(Cayla-Invivogen Europe, Toulouse, France);
A740003 from Tocris Bioscience, Pittsburgh, PA,
USA); poly-L-lysine hydrobromide (mol wt 70,000–
150,000), papain, DNase I (bovine pancreas), trypsin
inhibitor, L-leucyl-L-leucine methyl ester (L-LME),
protease inhibitor cocktail, Pefabloc® SC (100 mM),
CU-CPT22, and all other biochemicals were pur-
chased from Sigma-Aldrich (Milan, Italy) unless
noted otherwise; recombinant human Apo-SAA (con-
sensus SAA molecule corresponding to human
Apo-SAA1α, except for the presence of an N-terminal
methionine, the substitution of asparagine for aspartic
acid at position 60, and arginine for histidine at pos-
ition 71) from Peprotech (endotoxin level < 0.1 ng/μg
protein; London, UK); QIAzol from Qiagen (Milan,
Italy. Falcon tissue culture plastic-ware were purchased
from BD Biosciences. Sterilin Petri plastic dishes
(10 cm Ø) were obtained from Sarstedt (Verona, Italy).
Cell culture
Microglia were isolated from mixed glial cell cultures
as previously described [34]. All experiments were
conducted in compliance with Italian Ministry of
Health (art. 31, D.L. 26/2014) guidelines for the care
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and use of laboratory animals and were approved by
the Institutional Animal Care and Use Committee of
the University of Padua (958/2016-PR). In brief, cells
dissociated from postnatal day 1 rat pups (Charles
River, Calco, Italy; strain: CD) cerebral cortices were
plated in 75 cm2 poly-L-lysine-coated tissue culture
flasks (1.5 brains per flask) and grown in high-glucose
Dulbecco’s modified Eagle’s medium (DMEM) with
2 mM glutamine, 50 units/ml penicillin/50 μg/ml
streptomycin, 50 μg/ml gentamycin, and 10% FCS
(‘growth medium’). Culture medium was changed
after 24 h. The cultures reached confluence by 7 days
at which time microglia were recovered by shaking
the flasks on an orbital shaker at 200 rpm for 1 h
(37 °C). The remaining cell monolayers were highly
enriched in astrocytes (< 5% microglia, as determined
by flow cytometry using cell type-specific antibodies)
[35]. The culture supernatant containing microglia
was transferred to Sterilin plastic Petri dishes and in-
cubated for 45 min at 37 °C (5% CO2, 95% air) to
allow adhesion of microglia. The adherent microglial
cells (> 99% pure, as determined by flow cytometry using
cell type-specific antibodies) [35] were detached by mech-
anically scraping into growth medium and re-plated in
this same medium, on poly-L-lysine-coated 24-well or
96-well culture plates (250,000 and 50,000 cells per well
for mRNA and cytokine analysis, respectively). For some
experiments, the astrocyte monolayers were depleted of
residual microglia using a 60-min exposure (50 mM) to
the lysosomotropic agent L-LME [36], as described previ-
ously [37, 38]. Astrocyte plating densities were the same
as used for microglia.
Quantitative real-time polymerase chain reaction (q-PCR)
Total RNA was extracted from cells by QIAzol,
according to the manufacturer’s instructions. RNA
integrity and quantity were determined by RNA 6000
Nano assay in an Agilent BioAnalyser (A260/280 ratio >
1.8). Reverse transcription was performed with Super-
script III reverse transcriptase (Invitrogen). The
q-PCR reaction was performed as described previously
[37]. Primer sequences are listed in Table 1. Amounts
of each gene product were calculated using linear re-
gression analysis from standard curves, demonstrating
amplification efficiencies ranging from 90 to 100%.
Dissociation curves were generated for each primer
pair, showing single product amplification. Data are
normalized to β-actin mRNA level.
IL-1β production and release
Purified microglia and enriched astrocytes were plated
in poly-L-lysine coated 96-well plates (50,000 cells per
well) in growth medium and allowed to adhere over-
night. These plating densities do not affect glial cell
vitality/function [39, 40]. Cells were primed by
pre-treating with 0.1 μg/ml LPS (optimal concentration
chosen from preliminary experiments) [18, 37, 41] or
different concentrations of recombinant human Apo-SAA
(as indicated in the experiment) for 2 h in serum-free cul-
ture medium prior to stimulation with 5 mM ATP [41]
for 1 h. None of the treatments, at the concentrations
tested, affected cell viability (data not shown; see also [12,
42–44]). Cell supernatants were collected and stored at −
20 °C until the day of assay (avoiding repeated freeze-thaw
cycles). Cell lysates were prepared by adding to each
96-well culture 100 μl lysis solution containing: 89 μl
NP40 lysis buffer, 10 μl of 10× protease inhibitor cocktail,
and 1 μl of 100 mM Pefabloc SC. IL-1β content of culture
medium and cell lysates was analyzed using commercially
available enzyme-linked immunosorbent assay (ELISA)
kits according to the manufacturer’s instructions (Antige-
nix America, Huntington Station, NY, USA). Standards
with known amounts of IL-1β and TNF-α were used to
convert values into absolute concentrations of the cyto-
kine in pg/ml.
Statistics
Data are given as mean ± sem, unless stated otherwise.
Statistical analyses to determine group differences were
performed either by two-sample equal variance Student’s
t test, or by one-way analysis of variance followed by
Dunnett’s or Bonferroni’s post hoc tests for comparisons
involving more than two data groups. Significance was
taken at p < 0.05.
Table 1 PCR primers used in this study
Gene target Direction Sequence
β-ACT F 5′-CCCCATTGAACACGGCATTGTCA-3′
R 5′-ACCCTCATAGATGGGCACAGTGT-3′
IL-1β F 5′-TGTGGCAGCTACCTATGTCT-3′
R 5′-GGGAACATCACACACTAGCA-3′
NLRP3 F 5′-TGATGCATGCACGTCTAATCTC-3′
R 5′-CAAATCGAGATGCGGGAGAG-3′
SAA1 F 5′-ACACGGAGCAGAGGACTCAAG-3′
R 5′-GGTCGAAAGTGGTTGGGGTC-3′
TNF-α F 5′-CATCTTCTCAAAACTCGAGTGACAA-3′
R 5′-TGGGAGTAGATAAGGTACAGCCC-3′
TLR2 F 5′-TCCATGTCCTGGTTGACTGG-3′
R 5′-AGGAGAAGGGCACAGCAGAC-3′
TLR4 F 5′-GATTGCTCAGACATGGCAGTTTC-3′
R 5′-CACTCGAGGTAGGTGTTTCTGCTAA-3′
β-ACT β-actin, SAA serum amyloid A, IL-1β intereukin-1β, TNF-α tumor necrosis
factor α, NLRP3 inflammasome, TLR toll-like receptor. F forward, R reverse
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Results
SAA upregulates NLRP3 and IL-1β mRNA in rat primary
microglia
SAA mediates cytokine production by a variety of
non-neural cell types [45], as well as primary microglia
[12]. However, it is not known if SAA is able also to up-
regulate expression of the NLRP3 inflammasome gene
in CNS-derived glia. Incubation of rat primary
cortical microglia with Apo-SAA resulted in a
time-dependent rise in Nlrp3 expression that peaked
at 3 h (Fig. 1, solid bars); a similar time-course was
observed when microglia were stimulated with LPS
(Fig. 1, shaded bars). Relative expression levels
appeared higher for Apo-SAA than for LPS-treated
cells (optimal concentrations chosen for Apo-SAA
and LPS were based on preliminary experiments; see
also [12, 35]). The kinetics of Tnf-α expression in
Apo-SAA- and LPS-stimulated microglia mirrored
that seen for NLRP3 mRNA (Additional file 1: Figure
S1). Interestingly, the expression level of Il-1β in both
Apo-SAA- and LPS-treated cells peaked already at
3 h (Fig. 2, solid and shaded bars, respectively) and
remained at plateau through 24 h for Apo-SAA. In
contrast, intracellular content of IL-1β peaked at 6 h
in both Apo-SAA- and LPS-treated microglia and
then declined, although remained above basal up to
24 h (Additional file 2: Figure S2). Exposure of micro-
glia to either Apo-SAA or LPS led to a gradual
up-regulation of Saa1 over the 24-h study period
(Fig. 3, solid and shaded bars, respectively), suggesting
a potential autocrine/paracrine effect of SAA. Again,
the effect of Apo-SAA was more robust than that of
LPS in terms of relative expression levels for Saa1.
SAA primes cortical and cerebellar microglia for ATP- and
P2X7R-dependent IL-1β release
In the brain, IL-1β is mainly produced by activated
microglia [46], and ATP-dependent/P2X7R-triggered
IL-1β maturation and export is believed to contribute
significantly to this cytokine pool in nervous system
Fig. 1 Treatment of rat cortical microglia with Apo-SAA or LPS
upregulates in a time-dependent manner mRNA for NLRP3. Cultures
were treated the day after plating with 0.5 μg/ml recombinant
human Apo-SAA or 0.1 μg/ml LPS and processed 1, 3, 6, and 24 h
later for q-PCR, as detailed in the “Methods” section. Data are
presented as relative expression level (normalized with respect to
β-actin (βACT)) at each time point and are mean ± sem, n = 6.
Control values (which were at the limit of detection) were omitted
for clarity. Apo-SAA (■); LPS (▓). For LPS, *p < 0.05 and **p < 0.01 vs
1 h; for Apo-SAA, °°p < 0.01 and °°°p < 0.001 vs 1 h
Fig. 2 Treatment of rat cortical microglia with Apo-SAA or LPS
upregulates in a time-dependent manner mRNA for IL-1β. Cultures
were treated the day after plating with 0.5 μg/ml recombinant
human Apo-SAA or 0.1 µg/ml LPS and processed 1, 3, 6, and 24 h
later for q-PCR, as detailed in the “Methods” section. Data are
presented as relative expression level (normalized with respect to
β-actin (βACT)) at each time point and are mean ± sem, n = 3.
Control values (which were at the limit of detection) were omitted
for clarity. Apo-SAA (■); LPS (▓). For Apo-SAA, °°°p < 0.001 vs 1 h
Fig. 3 Treatment of rat cortical microglia with Apo-SAA or LPS
upregulates in a time-dependent manner mRNA for SAA1. Cultures
were treated the day after plating with 0.5 μg/ml recombinant
human Apo-SAA or 0.1 µg/ml LPS and processed 1, 3, 6, and 24 h
later for q-PCR, as detailed in the “Methods” section. Data are
presented as relative expression level (normalized with respect to
β-actin (βACT)) at each time point and are mean ± sem, n = 6.
Control values (which were at the limit of detection) were omitted for
clarity. Apo-SAA (■); LPS (▓). For LPS, *p < 0.05 vs 1 h; for Apo-SAA,
°°°p < 0.001 vs 1 h, **p < 0.01 vs 1 h, and ***p < 0.001 vs 6 h
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pathologies [20, 23]. TLR4/TLR2 signaling pathways may
be involved in neurodegenerative disorders including
motor neuron disease [47], cerebral hypoxia-ischemia
[48, 49] and blood-spinal cord barrier dysfunction after
ischemia/reperfusion injury [50], and neuropathic pain
[51]. Using a protocol established for TLR agonist
priming of primary CNS glia [38], cortical microglia
were first incubated with different concentrations of
Apo-SAA for 2 h in serum-free medium followed by
addition of ATP to a final concentration of 5 mM. After a
further 60 min of incubation, cell culture medium and cell
lysates were collected for measurement of IL-1β by ELISA.
Incubation with Apo-SAA only (no ATP) led to a
concentration-dependent accumulation of intracellular
IL-1β that was already maximal at 0.5 μg/ml Apo-SAA,
with very little IL-1β in the culture medium (left half of
Fig. 4a, b, respectively). Conversely, incubation with
Apo-SAA/ATP produced a concentration-dependent ac-
cumulation of IL-1β in the culture medium (again max-
imal at 0.5 μg/ml Apo-SAA), with a concomitant loss of
intracellular IL-1β (right half of Fig. 4a and b, respectively,
solid bars). Qualitatively similar effects were seen with
0.1 μg/ml LPS (maximal effective concentration), although
once again the magnitude of cytokine production was
greater for Apo-SAA.
Routinely used methods for preparing rodent primary
astrocyte cell cultures generally contain variable, small
percentages (up to 5%) of contaminating microglia [52]. A
number of studies have demonstrated that inflammatory
mediator output from enriched astrocytes is dependent on
the presence of residual microglia [12, 37, 38, 53, 54]. Util-
izing the lysosomotropic agent L-LME [55] to remove any
remaining microglia [36–38, 56–58], purified cortical as-
trocytes were unresponsive to priming by Apo-SAA, as
observed earlier when using LPS [38] (data not shown).
To interrogate a role for P2X7R in the Apo-SAA/
ATP-mediated IL-1β release, microglia were pre-
treated 30 min with the selective P2X7R antagonist
A740003 [59], then primed 2 h with Apo-SAA
followed by a further 1-h incubation with ATP. The
expected rise in intracellular IL-1β caused by expos-
ure to either Apo-SAA or LPS was unaffected by
A740003, while the fall in intracellular IL-1β in cells
treated with Apo-SAA or LPS and ATP did not occur
(Fig. 5a). In contrast, A740003 prevented the increase
in extracellular IL-1β in Apo-SAA- or LPS-primed rat
cortical microglia treated with ATP (Fig. 5b). These
observations most likely are a consequence of block-
ing P2X7R-dependent cleavage of IL-1β precursor to
the releasable mature form of the cytokine.
Purified microglia cultured from rat cerebellum also
respond to ATP-dependent IL-1β release upon priming
with TLR2, TLR3, and TLR4 isoform agonists, in a
P2X7R-dependent manner [38].
To determine if this is also the case for priming
with Apo-SAA, cerebellar microglia were incubated
for 2 h with 0.5 μg/ml recombinant human Apo-SAA
followed by addition of ATP to 5 mM or culture
medium only. As Fig. 6a shows, Apo-SAA caused a
clear rise in the intracellular content of IL-1β, which
was markedly diminished in the presence of ATP.
Conversely, IL-1β in the culture medium increased
for Apo-SAA + ATP-treated cells. Qualitatively analo-
gous results were obtained using LPS (Fig. 6b), as
seen previously [38].
Fig. 4 Extracellular ATP causes release of IL-1β from rat cortical
microglia primed with Apo-SAA or LPS. Cortical microglia cultured in
96-well plates were first incubated 2 h with 0.05–1.5 μg/ml
recombinant human Apo-SAA or 0.1 μg/ml LPS. ATP was then
added to a final concentration of 5 mM as indicated by upper
horizontal bar. After a further 60-min incubation, cell lysates (a) and
culture medium (b) were collected for IL-1β analysis by ELISA. Note
that Apo-SAA was again a more efficacious priming stimulus than
was LPS. Control (CTRL). Apo-SAA (■); LPS (▓). Data are mean ± sem
(n = 6). a **p < 0.01 vs LPS only (no ATP). Apo-SAA at all
concentrations differed significantly with added ATP (p < 0.001)
compared to the same concentration with no ATP. b ***p < 0.001 vs
LPS only (no ATP). Apo-SAA at all concentrations differed
significantly with added ATP (p < 0.001) compared to the same
concentration with no ATP
Facci et al. Journal of Neuroinflammation  (2018) 15:164 Page 5 of 11
Apo-SAA modulates TLR2 and TLR4 gene expression in
cortical microglia
In purified primary rat cortical microglia, TLR4 and
TLR2 agonists have been reported to upregulate TLR2
mRNA expression while downregulating that of TLR4
[35]. Given that SAA is a putative agonist for both TLR4
and TLR2, we asked whether SAA could also affect Tlr2
and Tlr4 expression in cortical microglia. Apo-SAA
treatment of microglia time-dependently increased Tlr2,
with a peak at 3 h and a decline over 24 h (Fig. 7a). In
contrast, Tlr4 expression (normalized to β-actin) was
significantly reduced at 3, 6, and 24 h (Fig. 7b). In
confirmation of previous findings [35], LPS also raised
Tlr2 expression at 3 h, while downregulating that of
Tlr4 eat all time points (Additional file 3: Figure S3).
Several studies suggest that SAA is capable of activat-
ing TLR4 [24–27] and TLR2 [28–31]. To explore this in
the present setting, cortical microglia were first
pre-incubated for 30 min with either the TLR4 antagon-
ist CLI-095 [60] or the TLR2 antagonist CU-CPT22 [61].
The former (also known as TAK-242) suppresses specif-
ically TLR4 signaling, inhibiting the production of
pro-inflammatory cytokines [62]. CLI-095 acts by
Fig. 5 The P2X7R antagonist A740003 prevents the ATP-dependent
fall in intracellular IL-1β (a) and rise in extracellular IL-1β (b) in
Apo-SAA- or LPS-primed rat cortical microglia. Microglia cultured in
96-well plates were pretreated for 30 min with 10 μM A740003
(‘A74’) followed by a 2-h incubation with 0.5 μg/ml recombinant
human Apo-SAA (‘SAA’) or 0.1 μg/ml LPS. ATP was then added to
a final concentration of 5 mM. After a further 60-min incubation,
culture medium (b) and cell lysates (a) were collected for IL-1β analysis
by ELISA. Apo-SAA (▓); LPS (▄) Data are mean ± sem (n = 3).
***p < 0.001 vs LPS or LPS + ATP + A740003; °°°p < 0.001 vs Apo-SAA or
Apo-SAA + ATP + A740003. There were no statistically significant
differences between the LPS/LPS + A740003/LPS + ATP + A740003 and
Apo-SAA/Apo-SAA + A740003/Apo-SAA + ATP + A740003 groups
Fig. 6 Extracellular ATP causes release of IL-1β from purified rat
cerebellar microglia primed with Apo-SAA or LPS. Microglia cultured
in 96-well plates were first incubated 2 h with 0.5 μg/ml
recombinant human Apo-SAA (a) or 0.1 μg/ml LPS (b). ATP was
then added to a final concentration of 5 mM. After a further 60-min
incubation, culture medium (‘extra’) and cell lysates (‘intra’) were
collected for IL-1β analysis by ELISA. As for cortical microglia, here
also Apo-SAA was a more efficacious stimulus than was LPS (note
the difference in y-axis scales). Control (CTRL). Data are mean ± sem
(n = 6). ***p < 0.001: Apo-SAA vs Apo-SAA + ATP; or LPS vs LPS + ATP
(extracellular). °°°p < 0.001 vs Apo-SAA vs Apo-SAA + ATP; or LPS vs
LPS + ATP (intracellular)
Facci et al. Journal of Neuroinflammation  (2018) 15:164 Page 6 of 11
blocking signaling mediated by the intracellular domain
of TLR4, but not the extracellular domain, and sup-
presses both ligand-dependent and ligand-independent
signaling of TLR4 [62]. CU-CPT22 is reported to com-
pete with the synthetic triacylated lipoprotein
(Pam3CSK4) binding to TLR1/2 and repress downstream
signaling from IL-1β and TNF-α [61].
Subsequent addition of LPS (0.1 μg/ml), Apo-SAA
(0.5 μg/ml), or the TLR2 agonist Pam3CSK4 (0.3 μg/ml)
produced significant increases in the intracellular content
of IL-1β after both 3 and 24 h (Fig. 8, upper and lower
panels, respectively). CLI-095 pre-treatment fully blocked
the effect of LPS, and partially (but significantly, p < 0.001)
that of Apo-SAA at both time points. However, the stimu-
latory effect of Pam3CSK4 was unaffected by the TLR4
antagonist at 3 h, and modestly so at 24 h. CU-CPT22
failed to alter the stimulatory effect of Apo-SAA or LPS;
surprisingly, this TLR1/2 antagonist also was ineffective
when tested on cells challenged with the TLR1/2 agonist
Pam3CSK4—in contrast to earlier findings [61]. Similar re-
sults were obtained for TNF-α release from the same cells
(data (pg/ml) are mean ± sem, 3-h point): control,
CLI-095, and CU-CPT22-treated cells, 0; LPS, 311 ± 24;
Apo-SAA, 840 ± 102; Pam3CSK4, 322 ± 9; LPS + CLI-095,
0; Apo-SAA +CLI-095, 224 ± 3; Pam3CSK4 + CLI-095,
242 ± 12; LPS + CU-CPT22, 399 ± 23; Apo-SAA +
Fig. 7 Treatment of rat cortical microglia with Apo-SAA, in a time-
dependent manner, upregulates mRNA for TLR2 and downregulates
that for TLR4. Cultures were treated the day after plating with
0.5 μg/ml recombinant human Apo-SAA and processed 1, 3, 6, and
24 h later for q-PCR, as detailed in the “Methods” section. a TLR2.
b TLR4. Data are presented as relative expression level (normalized
with respect to β-actin (βACT)) at each time point and are mean ±
sem, n = 3 (n = 9 for 3 h). Control (CTRL; untreated) cultures.
***p < 0.001 vs CTRL for that time point; °°°p < 0.001 vs CTRL for that
time point. Note the difference in expression levels between TLR2 and
TLR4 mRNA
Fig. 8 Effect of the TLR4 antagonist CLI-095 and the TLR1/2
antagonist CU-CPT22 on intracellular IL-1β content in rat cortical
microglia treated with LPS, Apo-SAA, or Pam3CSK4. The day after
plating culture medium was replaced with 50 μl/well of serum-free
medium containing 1 μg/ml CLI-095 (‘CLI’) or 20 μM CU-CPT (‘CU’).
After 30-min incubation, equal volume of medium was added
containing 0.2 μg/ml LPS, 1 μg/ml recombinant human Apo-SAA, or
0.6 μg/ml Pam3CSK4. Final concentrations of all added agents were
thus one-half of the values indicated. After a further incubation of 3
and 24 h cell lysates were collected for IL-1β analysis by ELISA, as
detailed in the “Methods” section. (upper panel) 3 h; (lower panel)
24 h. Data are mean ± sem, n = 4. Control (CTRL; untreated) cultures.
*p < 0.05 and ***p < 0.001 vs CTRL; °p < 0.05 and °°°p < 0.001 vs LPS;
###p < 0.001 vs Apo-SAA; #p < 0.05 and vs Pam3CSK4
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CU-CPT22, 822 ± 76; 420 ± 3; CLI-095 fully eliminated
the effect of LPS and partially, but significantly, that of
Apo-SAA (p < 0.001).
Discussion
Growing evidence indicates that CNS disorders are char-
acterized by central activation of innate immunity, as
well as activation of a potent peripheral acute phase re-
sponse that influences central inflammation and leads to
poor disease outcome [5]. The acute phase response
plays a critical role in the innate immune response to
tissue injury [63]. Among acute phase proteins such as
C-reactive protein, complement proteins, and SAA, the
last one can be considered a “danger signal” that influ-
ences the inflammation process [64]. Its low basal level
and high inducibility are in keeping with danger signal
molecules [65], being produced in response to poten-
tially harmful environmental cues, including trauma, in-
fection, surgery, and severe stress. A number of studies
imply a role for SAA in inflammation-associated
neuropathologies [7–11], although the underlying mo-
lecular processes remain to be fully explored. Here, we
show that in neonatal cortical microglia, Apo-SAA
time-dependently upregulates NLRP3 inflammasome
and IL-1β mRNA expression and intracellular produc-
tion of IL-1β and stimulates release of IL-1β in the pres-
ence of ATP, a multi-target danger signal in the brain
[32] in a P2X7R-dependent manner. The rise in extracel-
lular release of IL-1β in the presence of ATP was accom-
panied by a fall in the intracellular content, consistent
with NLRP3/caspase 1-complex 1 activation and cleav-
age of the pro-form of IL-1β to the mature, active secreted
species [20–22]. The action of Apo-SAA was not limited
to cortical microglia, as similar ATP-dependent release of
IL-1β was also seen for cerebellar microglia. IL-1β is
viewed as a master regulator of neuroinflammation [13]
that contributes importantly to cellular activation and
cytokine production. This cytokine plays a key role in the
pathogenesis of acute and chronic diseases of both the per-
ipheral nervous system and CNS [15–17]. It merits men-
tion that the effects of Apo-SAA on gene expression and
cytokine production were of a far greater magnitude than
those obtained using the optimal concentration of LPS as
benchmark, thus highlighting the pro-inflammatory po-
tency of this acute phase protein. Whether adult microglia
would respond differently was not tested.
A comparison of the SAA concentrations used in the
present investigation with levels of SAA previously de-
tected in human cerebrospinal fluid and plasma suggests
the potential for physiological relevance to the in vivo set-
ting. In one report, SAA levels in cerebrospinal fluid of
AD subjects were found to be much higher than in nor-
mal controls [8], and generally within the range of the
highest concentration used here. Serum concentrations
of SAA in relapsing-remitting MS patients have been
reported elevated with a mean level of 12.1 ± 8.7 μg/ml
[66], and significantly increased (mean value 10 μg/ml,
p = 0.030 vs. control) in neuromyelitis optica patients [67].
These values contrast with active concentrations of 0.15–
1.5 μg/ml in the present in vitro study.
An expanding body of data demonstrates that pharma-
cological or genetic manipulation of P2X7Rs alters their
responsiveness in animal models of CNS neurological
disorders [33, 68]. The P2X7R has been suggested to also
regulate the pathophysiology of psychiatric disorders, in-
cluding mood disorders [33]. P2X7R-triggered IL-1β
maturation and export is thus likely to represent an
important contributor to this cytokine pool [20, 23].
SAA is not detectable in normal brain but has been
reported in AD brain, together with its gene in MS
brain [7]. Miida et al. [8] described a raised SAA con-
centration in cerebrospinal fluid of AD. SAA immu-
noreactivity was reported to co-localize with amyloid
β-peptide deposits in AD brain [9]. P2X7R-positive
microglia surrounded amyloid plaques in a mouse
transgenic AD model [69], and microglia around
amyloid plaques in AD brain are immunopositive for
IL-1β [70]. Collectively, these findings propose a link
between P2X7R, Apo-SAA, and IL-1β in AD patho-
physiology. In addition, the ability of Apo-SAA to
regulate its own gene expression suggests the poten-
tial for autocrine/paracrine effects of SAA. Since
microglia in the AD brain adopt distinct functional
and molecular phenotypes, it is conceivable that the
response of “AD microglia” to SAA would differ from
that of wild-type microglia.
A number of reports indicate the capability of SAA to
act as an agonist for both TLR4 [24–27] and TLR2
[28–31, 71]. Ligand engagement of TLR4 by LPS and
TLR2 by Pam3CSK4 leads to the upregulation of Tlr2
and downregulation of Tlr4 in cortical microglia [35].
Consistent with its putative action as a ligand for both
TLR2 and TLR4, Apo-SAA produced a time-dependent
robust and significant increase in Tlr2 expression in
cortical microglia, with a concomitant reduction in the
relative level of Tlr4. Conceivably, this action of SAA
could result in a ‘feed-forward’ mechanism, whereby
SAA increases expression of its receptor and amplifica-
tion of a priming response. Attempts at using pharma-
cological tools to dissect participation of TLR4 and
TLR2 in the actions of Apo-SAA were equivocal. The
selective TLR4 antagonist CLI-095 completed blocked
the ability of LPS to synthesize/release IL-1β and par-
tially, but significantly, that of Apo-SAA. While the
TLR2 antagonist CU-CPT22 failed to alter the stimula-
tory effect of Apo-SAA or LPS, it also proved ineffect-
ive on microglia treated with the TLR1/2 agonist
Pam3CSK4. Our inability to confirm the earlier report
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for CU-CPT22 action against Pam3CSK4 [61] could be
due to differences in cell type used (primary microglia vs
RAW264.7 macrophages) or treatment times (not speci-
fied in [61]), even though we used two incubation times
and the same concentrations of ligand and antagonist as
in [61]. Another consideration is that CU-CPT22 was de-
signed to compete with Pam3CSK4 binding to TLR1/2,
thus disrupting formation of the TLR1/TLR2 heterodimer
[61]. Although outside the scope of the present study, the
use of microglia from TLR2−/− animals could provide a
tool to address this question.
A failure of remyelination is responsible, in large part,
for the long-term neurologic consequences of MS. An
intriguing study by Sloane et al. [72] described upregu-
lated TLR2 expression by oligodendrocytes in MS le-
sions, with pathogen-derived TLR2 agonists, but not
agonists for other TLRs, inhibiting oligodendrocyte pre-
cursor cell (OPC) maturation in vitro. Ablated expres-
sion of TLR2 also enhanced remyelination in a
lysolecithin animal model of MS [72]. Intense immuno-
histochemical staining of SAA has been detected in the
brains of patients with neurologically confirmed MS in
comparison to an unaffected region and non-MS brains,
with the major site of staining being the myelin sheaths
of axons in affected cortex [11]. Pro-inflammatory cyto-
kines such as IL-1β and TNF-α [73] may play important
roles in expression of SAA1 and SAA2. The pathophysi-
ology of a variety of neurological disorders, including
MS, is associated with TNF-α [74, 75], a master
pro-inflammatory product of activated microglia and
peripheral macrophages implicated in the pathogenesis
of CNS demyelination [76, 77]. Apo-SAA treatment of
rat cortical microglia increased production of TNF-α and
IL-1β, while TNF-α time-dependently raised Saa1 expres-
sion in cultured OPCs [12]. Our findings in the context of
the above considerations, together with evidence for
P2X7R in the development of experimental autoimmune
encephalomyelitis [78] and microglia-oligodendrocyte
crosstalk [79], propose a vicious cycle of Apo-SAA, IL-1β,
and TLR2 leading to the demise of OPCs.
Conclusions
CNS disorders are characterized by central activation of
innate immunity and activation of a potent peripheral
acute phase response that influences central inflamma-
tion and contributes to poor outcome. Our data show
that in microglia, the acute phase protein Apo-SAA
upregulates NLRP3 inflammasome and IL-1β mRNA ex-
pression and intracellular production of IL-1β and stim-
ulates release of IL-1β in the presence of ATP in a
P2X7R-dependent manner. Apo-SAA upregulated ex-
pression of its own gene and that of TLR2, suggesting a
potential ‘feed-forward’ mechanism, whereby SAA in-
creases expression of its receptor and amplification of a
priming response. The effects of Apo-SAA on gene expres-
sion and cytokine production were of a far greater magni-
tude than those observed with the classical TLR4 agonist
lipopolysaccharide, highlighting the pro-inflammatory po-
tency of this acute phase protein. Given the evidence for
P2X7Rs involvement in CNS neurological disorders and
expression of SAA in AD and MS brain, the findings pre-
sented here propose a link between P2X7R, SAA, and
IL-1β in CNS pathophysiology.
Additional files
Additional file 1: Figure S1. Treatment of rat cortical microglia with
Apo-SAA or LPS upregulates, in a time-dependent manner mRNA for
TNF-α. Cultures were treated the day after plating with 0.5 μg/ml
recombinant human Apo-SAA or 0.1 µg/ml LPS and processed 1, 3, 6,
and 24 h later for q-PCR, as detailed in the “Methods” section. Data are
presented as relative expression level (normalized with respect to β-actin
(βACT)) at each time point and are mean ± sem, n = 3. Control values
(which were at the limit of detection) were omitted for clarity. Apo-SAA
(■); LPS (▓). For LPS, *p < 0.05 vs 1 and 24 h; for Apo-SAA: °°°p < 0.001 vs
1, 6, and 24 h. (TIF 468 kb)
Additional file 2: Figure S2. Treatment of rat cortical microglia with
Apo-SAA or LPS upregulates, in a time-dependent manner, intracellular
content of IL-1β. Cultures were treated the day after plating with
0.5 μg/ml recombinant human Apo-SAA or 0.1 µg/ml LPS and processed 1,
3, 6, and 24 h later for measurement of intracellular IL-1β, as detailed in the
“Methods” section. Apo-SAA (■); LPS (▓). Data are expressed as mean ± sem,
n = 3. The quantity of intracellular IL-1β in unstimulated cells was below the
detection limit of the ELISA assay kit. For LPS, **p < 0.01 vs 3 and 6 h; for
Apo-SAA, °°°p < 0.001 vs 1 h, ***p < 0.001 vs 3 and 24 h. (TIF 485 kb)
Additional file 3: Figure S3. Treatment of rat cortical microglia with
LPS, in a time-dependent manner, upregulates mRNA for TLR2 and
downregulates that for TLR4. Cultures were treated the day after plating
with 0.1 μg/ml LPS and processed 1, 3, 6, and 24 h later for q-PCR, as
detailed in the “Methods” section. (a) TLR2. (b) TLR4. Data are presented
as relative expression level (normalized with respect to β-actin (βACT)) at
each time point and are mean + sem, n = 3. Control (CTRL; untreated)
cultures. Data are expressed as mean ± sem, n = 3 (n = 9 for 3 h). (a)
**p < 0.01 vs CTRL (3 h) and ***p < 0.001 vs CTRL (6 h). (b) *p < 0.05 vs
CTRL (3 h), ***p < 0.001 vs CTRL for that time point. Note the difference
in expression levels between TLR2 and TLR4 mRNA. (TIF 957 kb)
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